Preparation and Characterization of Camptothecin Solid Lipid Nanoparticles

REFERENCES

• Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., Sim G.A. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966; 88: 3888–3890
   Web of Science ®Google Scholar
• Potmesil M. Camptothecins: from Bench Research to Hospital Wards. Cancer Res. 1994; 54: 1431–1439
   PubMed Web of Science ®Google Scholar
• Hsiang Y.-H., Lihou M.G., Liu L.F. Arrest of Replication Forks by Drug-Stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin. Cancer Res. 1989; 49: 5077–5082
   PubMed Web of Science ®Google Scholar
• Burke T.G., Mi Z. The Structural Basis of Camptothecin Interactions with Human Serum Albumin Impact on Drug Stability. J. Med. Chem. 1994; 37: 40–46
   PubMed Web of Science ®Google Scholar
• Supko J.G., Malspeis L. Pharmacokinetics of the 9-Amino and 10,11 Methylenedioxy Derivatives of Camptothecin in Mice. Cancer Res. 1993; 53: 3062–3069
   PubMed Web of Science ®Google Scholar
• Beijnen J.H. High-Performance Liquid Chromatographic Analysis of the Antitumour Drug Camptothecin and Its Lactone Ring-Opened Form in Rat Plasma. J. Chromatogr. Biomed. Appl. 1993; 617: 111–117
   Google Scholar
• Burke T.G., Gao X. Stabilization of Topotecan in Low pH Liposomes Composed of Distearoylphosphatidylcholine. J. Pharm. Sci. 1994; 83: 967–969
   PubMed Web of Science ®Google Scholar
• Zhang R., Li Y., Cai Q., Liu T., Sun H., Chambless B. Preclinical Pharmacology of the Natural Product Anticancer Agent 10-Hydroxycamptothecin, an Inhibitor of Topoisomerase I. Cancer Chemother. Pharmacol. 1998; 41: 257–267
   PubMed Web of Science ®Google Scholar
• Davies B.E., Minthorn E.A., Dennis M.J., Rosing H., Beijnen J.H. The Pharmacokinetics of Topotecan and Its Carboxylate Form Following Separate Intravenous Administration to Dog. Pharm. Res. 1997; 14: 1461–1465
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J.M., Pugh S., Polin L., Jones J., Corbett T., Cooper E., Liversidge G.G. Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs. Pharm. Res. 1996; 13: 272–278
   PubMed Web of Science ®Google Scholar
• Shenderova A., Burke T.G., Schwendeman S.P. Stabilization of 10-Hydroxycamptothecin in Poly-(Lactide-co-Glycolide) Microsphere Delivery Vehicles. Pharm. Res. 1997; 14: 1406–1414
   PubMed Web of Science ®Google Scholar
• Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body Distribution in Mice of Intravenous Injected Camptothecin Solid Lipid Nanoparticles and Targeting Effect on Brain. J. Contr. Rel. 1999; 59(3)299–307
   PubMed Web of Science ®Google Scholar
• Yang S., Zhu J., Lu Y., Liang B., Yang C. Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration. Pharm. Res. 1999; 16(5)751–757
   PubMed Web of Science ®Google Scholar
• Giovanella B.C., Hinz H.R., Kozielski A.J., Stehlin J.S., Silber R., Potmesil M. Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20-(S)-Camptothecin. Cancer Res. 1991; 51: 3052–3055
   PubMed Web of Science ®Google Scholar
• Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., Potmesil M. DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts. Science 1989; 246: 1046–1048
   PubMed Web of Science ®Google Scholar
• Müller R.H., Mader K., Gohla S. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery—A Review of the State of the Art. Eur. J. Pharm. Biopharm. 2000; 50(1)161–177
   PubMed Web of Science ®Google Scholar
• Schwarz C., Mehnert W., Lucks J.S., Müller R.H. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. I. Production, Characterization and Sterilization. J. Contr. Rel. 1994; 30: 83–96
   Web of Science ®Google Scholar
• Heiati H., Phillips N.C., Tawashi R. Evidence for Phospholipid Bilayer Formation in Solid Lipid Nanoparticles Formulated with Phospholipid and Triglyceride. Pharm. Res. 1996; 13: 1406–1410
   PubMed Web of Science ®Google Scholar
• Westesen K., Bunjes H., Koch M.H.J. Physicochemical Characterization of Lipid Nanoparticles and Evaluation of Their Drug Loading Capacity and Sustained Release Potential. J. Contr. Rel. 1997; 48: 223–236
   Web of Science ®Google Scholar
• Müller R.H., Maassen S., Schwarz C., Mehnert W. Solid Lipid Nanoparticles (SLN) as Potential Carrier for Human Use: Interaction with Human Granulocytes. J. Contr. Rel. 1997; 47: 261–269
   Web of Science ®Google Scholar
• Müller R.H., Maassen S., Weyhers H., Mehnert W. Phagocytic Uptake and Cytotoxicity of Solid Lipid Nanoparticles (SLN) Sterically Stabilized with Poloxamine 908 and Poloxamer 407. J. Drug Target 1996; 4: 161–170
   PubMed Web of Science ®Google Scholar
• Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface Modification of Nanoparticles to Oppose Uptake by Mononuclear Phagocyte System. Adv. Drug Del. Rev. 1995; 17: 31–48
   Web of Science ®Google Scholar
• Stolnik S., Illum L., Davis S.S. Long Circulating Microparticulate Drug Carriers. Adv. Drug Del. Rev. 1995; 16: 195–214
   Web of Science ®Google Scholar
• Taguchi G. Taguchi Method: Design of Experiments, S. Konishi. Quality Engineering Series, 1993; Vol. 4
   Google Scholar
• Vold R.D., Vold M.J. Colloid and Interface Chemistry. Addison-Wesley. 1983
   Google Scholar
• Supko J.G., Malspeis L. A Reversed-Phase HPLC Method for Determining Camptothecin in Plasma with Specificity for the Intact Lactone Form of the Drug. J. Liq. Chromatogr. 1991; 14: 1779–1803
   Web of Science ®Google Scholar
• Zimmermann E., Müller R.H., Mader K. Influence of Different Parameters on Reconstitution of Lyophilized SLN. Int. J. Pharm. 2000; 196(2)211–213
   PubMed Web of Science ®Google Scholar
• Schwarz C., Mehnert W. Freeze-Drying of Drug-Free and Drug-Loaded Solid Lipid Nanoparticles (SLN). Int. J. Pharm. 1997; 157(2)171–179
   PubMed Web of Science ®Google Scholar
• Folkersma R., van Diemen A.J.G., Stein H.N. Electrophoretic Properties of Polystyrene Spheres. Langmuir 1998; 14: 5973–5976
   Web of Science ®Google Scholar
• Cavalli R., Aquilano D., Carlotti M.E., Gasco M.R. Study by X-ray Powder Diffraction and Differential Scanning Calorimetry of Two Model Drugs, Phenothiazine and Nifedipine, Incorporated into Lipid Nanoparticles. Eur. J. Pharm. Biopharm. 1995; 41(5)329–333
   Web of Science ®Google Scholar
• Cavalli R., Peira E., Caputo O., Gasco M.R. Solid Lipid Nanoparticles as Carriers of Hydrocortisone and Progesterone Complexes with beta-Cyclodextrins. Int. J. Pharm. 1999; 182(1)59–69
   PubMed Web of Science ®Google Scholar
• zur Muhlen A., Schwarz C., Mehnert W. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery-Drug Release and Release Mechanism. Eur. J. Pharm. Biopharm. 1998; 45(2)149–155
   PubMed Web of Science ®Google Scholar
• Jenning V., Schafer-Korting M., Gohla S. Vitamin A-Loaded Solid Lipid Nanoparticles for Topical Use: Drug Release Properties. J. Contr. Rel. 2000; 66(2/3)115–126
   PubMed Web of Science ®Google Scholar